白消安-氟达拉滨预处理方案对异基因造血干细胞移植后肝静脉闭塞症的影响

摘要

Aim:To explore the safety of Busulfan-Fludarabine (Bu-Flud) regimen in patients given allogeneic hematopoietic stem cell transplantation (allo-HSCT) without prophylaxis of HVOD.Methods:Clinical data of 122 patients who received allo-HSCT conditioned with Bu-Flud regimen from December 2006 to June 2012 were analyzed,including 42 patients given low dose heparin for the prevention of HVOD,and 80 patients not given the prophylaxis of HVOD.The occurrence of HVOD was observed.Results:None of the 122 patients developed HVOD (0％),including unrelated donor transplantation,HLA haploidentical transplantation,patients with a history of hepatitis B and abnormal liver function prior to transplantion.Conclusion:It is safe for the patients who received allo-HSCT conditioned with Bu-Flud regimen without the prophylaxis of HVOD.%目的:探讨白消安(BU)联合氟达拉滨(Flud)预处理方案在无任何预防措施情况下对异基因造血干细胞移植后肝静脉闭塞症(HVOD)的影响.方法:分析以Bu-Flud为预处理方案的122例异基因造血干细胞移植(allo-HSCT)患者的临床资料,其中42例用小质量分数肝素预防HVOD,而80例则不予任何药物预防,并观察了两组HVOD发生情况.结果:两组均未发生HVOD,包括非亲缘供者移植和HLA单倍体相合供者移植,有乙型肝炎病史者,移植前转氨酶水平和总胆红素水平增高者.结论:以Bu-Flud为预处理方案的allo-HSCT患者,即使无HVOD预防也是安全的.